Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.62 |
| ▸ | BCHE | P06276 | 8/20 | 0.57 |
| ▸ | BACE1 | P56817 | 8/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22498123 | 0.98 | ACHE (0.61) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL21419827 | 0.89 | CYP2D6 (0.66) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL22755862 | 0.89 | CYP2D6 (0.66) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL2005970 | 0.89 | ACHE (0.67) | ACHEBCHEBACE1CCR3ALDH1A1 | |
| SCHEMBL14742553 | 0.84 | FUCA1 (0.60) | ACHECCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1286699 | 0.81 | ACHE (0.79) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL359069 | 0.81 | ACHE (0.79) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL358435 | 0.81 | ACHE (0.79) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL20624040 | 0.80 | ACHE (0.60) | ACHEBCHEBACE1CCR3CYP1A2 | |
| SCHEMBL1848011 | 0.79 | ACHE (0.59) | ACHEBCHEBACE1CCR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3947394-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939521-A | Imidazoline derivatives as CXCR4 modulators | 巴黎大学 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020201096-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201096-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | ACHE 4865/4885BCHE 4882/4885BACE1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.